ZLN005
目录号 : GC13437
A small molecule activator of PGC-1α expression
Cas No.:49671-76-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
ZLN005 is a novel transcriptional regulator of PGC-1α [1].
Peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) is an inducible coregulator that regulates energy metabolism. PGC-1α regulates glucose and fatty acid metabolism, mitochondrial biogenesis and so on. Dysregulation of PGC-1α is correlated with insulin resistance and type 2 diabetes mellitus [1].
ZLN005 is a novel PGC-1α transcriptional regulator. In the PGC-1α promoter reporter assay, ZLN005 potently inhibited luciferases. In L6 myotubes, ZLN005 dose-dependently increased PGC-1α mRNA levels. ZLN005 (10 μM) increased the mRNA levels of cytochrome c oxidase 5b (cox5b), acyl-CoA oxidase, strogen-related receptor α (ERRα), NRF1 and GLUT4. ZLN005 (20 μM) increased glucose uptake and oxidation of palmitic acid by 1.8-fold and 1.28-fold respectively in a dose dependent way. In L6 myotubes transfected with PGC-1α siRNA, ZLN005-stimulated oxidation of palmitic acid and expression of the PGC-1α gene was blocked. In L6 myotubes, ZLN005 increased the phosphorylation of AMPK and acetyl-CoA carboxylase (ACC) [1].
In db/db mice, ZLN005 reduced RER, suggesting a shift to fatty acid use. ZLN005 significantly reduced fasting blood glucose and random blood glucose levels. Also, ZLN005 improved glucose clearance and pyruvate tolerance and reduced insulin resistance [1].
Reference:
[1]. Zhang LN, Zhou HY, Fu YY, et al. Novel Small-Molecule PGC-1a Transcriptional Regulator With Beneficial Effects on Diabetic db/db Mice. Diabetes, 2013, 62(4): 1297-1307.
| Cas No. | 49671-76-3 | SDF | |
| 化学名 | 2-(4-tert-butylphenyl)-1H-benzimidazole | ||
| Canonical SMILES | CC(C)(C)C1=CC=C(C=C1)C2=NC3=CC=CC=C3N2 | ||
| 分子式 | C17H18N2 | 分子量 | 250.34 |
| 溶解度 | ≥ 23.3mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.9946 mL | 19.9728 mL | 39.9457 mL |
| 5 mM | 0.7989 mL | 3.9946 mL | 7.9891 mL |
| 10 mM | 0.3995 mL | 1.9973 mL | 3.9946 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。